- Home
- GBLI vs AVIR Comparison
GBLI vs AVIR Comparison
Compare GBLI & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GBLI | AVIR |
|---|---|---|
| Founded | 2016 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 398.7M | 399.3M |
| IPO Year | 2010 | 2020 |
Fundamental Metrics
Financial Performance| Metric | GBLI | AVIR |
|---|---|---|
| Price | $27.00 | $4.80 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 11.8K | ★ 319.9K |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | ★ 5.13% | N/A |
| EPS Growth | N/A | ★ 3.00 |
| EPS | ★ 0.29 | N/A |
| Revenue | ★ $450,098,000.00 | $351,367,000.00 |
| Revenue This Year | $14.23 | N/A |
| Revenue Next Year | $9.68 | N/A |
| P/E Ratio | $93.10 | ★ N/A |
| Revenue Growth | ★ 2.02 | N/A |
| 52 Week Low | $24.28 | $2.78 |
| 52 Week High | $31.44 | $6.45 |
Technical Indicators
Market Signals| Indicator | GBLI | AVIR |
|---|---|---|
| Relative Strength Index (RSI) | 58.36 | 52.35 |
| Support Level | $25.76 | $4.61 |
| Resistance Level | $28.78 | $5.04 |
| Average True Range (ATR) | 0.54 | 0.22 |
| MACD | 0.20 | -0.01 |
| Stochastic Oscillator | 66.67 | 46.25 |
Price Performance
Historical ComparisonAbout GBLI Global Indemnity Group LLC (DE)
Global Indemnity Group LLC is a United States-based holding company with a diversified portfolio of property and casualty insurance-related entities. Along with its subsidiaries, the company operates in the following reportable segments: Agency and Insurance Services, Belmont Insurance Companies - Core (Belmont Core), and Belmont Insurance Companies - Non-Core (Belmont Non-Core). Maximum revenue is generated from the Belmont Core segment, which offers direct insurance and assumed reinsurance products in the E&S (Excess and Surplus) marketplace. The Agency and Insurance Services segment is focused on sourcing, underwriting, and servicing primary and assumed reinsurance business; and specialized insurance service businesses providing technology, AI-enabled marketplace, and claims services.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.